<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
AstraZeneca (AZN) and Merck (MRK) announce that their PARP inhibitor Lynparza succeeds in meeting the primary endpoint in a late-stage study, evaluating it in first-line castration-resistant prostate cancer patients.
...read full article on Zacks Investment Research
